DTIL insider trading
NasdaqCM HealthcarePRECISION BIOSCIENCES INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About PRECISION BIOSCIENCES INC
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Company website: precisionbiosciences.com
DTIL insider activity at a glance
FilingIQ has scored 287 insider transactions for DTIL since Apr 1, 2019. The most recent filing in our index is dated Feb 18, 2026.
Across the full history, 26 open-market purchases
and 80 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on DTIL insider trades is 55.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest DTIL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for DTIL?
- FilingIQ tracks 287 Form 4 insider transactions for DTIL (PRECISION BIOSCIENCES INC), covering filings from Apr 1, 2019 onwards. 12 of those were filed in the last 90 days.
- Are DTIL insiders net buyers or net sellers?
- Across the full Form 4 history for DTIL, 26 transactions (9%) were open-market purchases and 80 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DTIL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is DTIL in?
- PRECISION BIOSCIENCES INC (DTIL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $93.52M.
Methodology & sources
Every DTIL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.